Table 5 Mono-factor analysis of postoperative survival rate of patients with NSCLC.
1-year postoperative survival rate(%) | P | 3-year postoperative survival rate(%) | P | 5-year postoperative survival rate(%) | P | |
|---|---|---|---|---|---|---|
Age | ||||||
≤60y | 91.1% | 0.978 | 67.9% | 0.780 | 64.3% | 0.225 |
>60y | 90.9% | 70.5% | 52.3% | |||
Gender | ||||||
Male | 93.8% | 0.055 | 73.8% | 0.040 | 62.5% | 0.155 |
Female | 80.0% | 50.0% | 45.0% | |||
Pathological type | ||||||
Adenocarcinoma | 92.5% | 0.777 | 72.5% | 0.873 | 57.5% | 0.409 |
Squamous cell carcinomas | 94.0% | 74.0% | 66.0% | |||
Tumor differentiation grade | ||||||
Poorly differentiated | 88.6% | 0.464 | 63.6% | 0.304 | 54.5% | 0.422 |
Middle-, high-differentiated | 92.9% | 73.2% | 62.5% | |||
Diameter of tumor | ||||||
≤4cm | 93.2% | 0.352 | 67.8% | 0.755 | 61.0% | 0.623 |
>4cm | 87.8% | 70.7% | 56.1% | |||
pTNM stage | ||||||
I stage | 97.7% | 0.126 | 79.1% | <0.001 | 69.8% | 0.001 |
II stage | 85.2% | 85.2% | 74.1% | |||
III stage | 86.7% | 40.0% | 30.0% | |||
Smoking status | ||||||
Yes | 93.2% | 0.352 | 74.6% | 0.148 | 62.7% | 0.365 |
No | 87.8% | 61.0% | 53.7% | |||
The plasma level of HIF-1α | ||||||
≤297.70 pg/ml | 96.2% | 0.061 | 76.9% | 0.075 | 63.5% | 0.345 |
>297.70 pg/ml | 85.4% | 60.4% | 54.2% | |||
